Professor of Pediatrics, University of Chicago Medicine
Pediatric Hematology & Oncology
Dr. Susan L. Cohn, MD
|
|
Give Review
Dr. Susan L. Cohn is an expert in the field of Pediatric Hematology & Oncology. He went to University of Illinois College of Medicine. He over the years received 8 awards: "Pediatrics Faculty Physician Peer Role Model Nominee", "Pritzker Scholar", "Chicago Innovator Award", "Joseph P. Brenneman Award", "Top Doctor in the Chicago Metro Area", "SIOP Award in the Discipline of Basic Science", "Nominated for the best clinical professor award" and "Super Doctor". Susan L. Cohn, MD is also published. He has 81 publications published. The lastest publication: "Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.'
Publications
- Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.
- Genetic discoveries and treatment advances in neuroblastoma.
- Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.
- A Selfless Act.
- Surveillance of Childhood Cancer Survivors: A Lifelong Affair.
- Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children's Oncology Group.
- Second malignancies in patients with neuroblastoma: The effects of risk-based therapy.
- Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project.
- Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project.
- TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.
- Secondary malignant neoplasms after high-dose chemotherapy and autologous stem Cell rescue for high-risk neuroblastoma.
- Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients.
- Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter⢠System.
- Time to Disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621).
- Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation.
- Erratum to: Targeting ALK: a promising strategy for the treatment of non-small cell lung Cancer, non-Hodgkin's lymphoma, and neuroblastoma.
- Neuroblastoma in older children, adolescents and young adults: A report from the international neuroblastoma risk group project.
- Purged versus non-purged peripheral blood stem-Cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
- Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Onco...
- Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
- Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group.
- Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression.
- Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival.
- Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed Disease following surgery alone.
- Genetically InFormed Therapies--A "GIFT" for Children with Cancer.
- Using germline genomics to individualize pediatric Cancer treatments.
- Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641.
- Locoregional MYCN-amplified neuroblastoma.
- Sorafenib inhibits neuroblastoma Cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
- Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project.
- Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study.
- Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age.
- Phase II Study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Child...
- ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux.
- Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project.
- Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project.
- Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma.
- Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
- Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone.
- Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study.
- The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.
- Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
- Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology ...
- Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma Cell lines and on tubulin polyme...
- Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
- Presence of Cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors.
- Progress in defining and treating high-risk neuroblastoma: lessons from the bench and bedside.
- The International Neuroblastoma Risk Group (INRG) classification System: an INRG Task Force report.
- Management of tumor lysis syndrome: need for evidence-based guidelines.
- Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project.
- Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.
- Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
- A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
- 3 + 3 not equal to (Rolling) 6.
- Prominent microvascular proliferation in clinically aggressive neuroblastoma.
- Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.
- High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene.
- Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
- School-based practice: physical therapists collaborating with physical education teachers. Give it a try!
- Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group s...
- A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
- Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
- The MYCN enigma: significance of MYCN expression in neuroblastoma.
- SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extraCellular matrix.
- ExCellent local tumor control regardless of extent of surgical resection after treatment on the Chicago Pilot II protocol for neuroblastoma.
- Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor Cell ploidy.
- Positive association between congenital anomalies and risk of neuroblastoma.
- Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
- Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
- Cross-talk between Schwann Cells and neuroblasts influences the biology of neuroblastoma xenografts.
- Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
- Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC.
- Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma.
- Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-Cell rescue: the experience at Children's Memorial Hospital.
- Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma.
- Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.
- Advances in the diagnosis and treatment of neuroblastoma.
- SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.
- Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-Cell rescue: results of the Chicago Pilot II Study.
- HuD, a neuronal-specific RNA-binding protein, increases the in vivo stability of MYCN RNA.
Schools
University Of Illinois College Of Medicine Chicago
Michael Reese Hospital
Children39s Memorial Hospital
Conditions Treated
- Adrenal Gland Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- Deep Vein Thrombosis (DVT)
- View All
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Health and Life PPO
- Platinum PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- Pediatrics Faculty Physician Peer Role Model Nominee
- Pritzker Scholar
- Chicago Innovator Award
- Joseph P. Brenneman Award
- Top Doctor in the Chicago Metro Area
- SIOP Award in the Discipline of Basic Science
- Nominated for the best clinical professor award
- Super Doctor
Education
-
McGaw Medical Center of Northwestern University -
University of Illinois College of Medicine -
Northwestern University
Hospital
-
University of Chicago Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. John F. Shern, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amina Rafique, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Sonali Chaudhury, MB
This Doctor is OpenDoctor Recommended.
|